Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

DSpace/Manakin Repository

Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
 
ARIA-MASK study group
(2020) Allergy, volume 75, issue 7, pp. 1546 - 1554
(Article)
Abstract
The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient.
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: allergy treatment, immunotherapy clinical, immunotherapy vaccines and mechanisms, Betacoronavirus/genetics, Asthma/complications, Humans, Sublingual Immunotherapy/methods, Th2 Cells/immunology, Pandemics/prevention & control, Rhinitis, Allergic/complications, COVID-19, Immunoglobulin M/metabolism, CD8-Positive T-Lymphocytes/immunology, SARS-CoV-2, Pneumonia, Viral/complications, Coronavirus Infections/complications, Eosinophils/immunology, Allergists/psychology, Immunoglobulin E/metabolism, Infection Control/methods, clinical immunotherapy, Immunology and Allergy, Immunology, Journal Article
DOI: https://doi.org/10.1111/all.14336
ISSN: 0105-4538
Publisher: Wiley-Blackwell
Note: Funding Information: LK declares grants and/or personal fees from Allergopharma, MEDA/Mylan, LETIPharma, Sanofi, HAL Allergie, Allergy Therapeutics, ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotek, and is a current member of the AeDA, DGHN, Deutsche Akademie fürAllergologie und KlinischeImmunologie, HNO‐BV GPA, and EAACI. MJ reports personal fees from ALK‐Abelló, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, LETIPharma, Biomay, HAL Allergy, AstraZeneca, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, and Chiesi. CA reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horizon's 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, SciBase, and advisory role in Sanofi/Regeneron. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, and others from KYomed INNOV. CB has received fees for delivering lectures. IA declares personal fees from Mundipharma, ROXALL, Sanofi, MSD, Faes Farma, Hikma, UCB, and AstraZeneca. B‐A reports grants and/or personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Mylan. AC reports grants and/or personal fees from GSK, AstraZeneca, Mylan Pharma, Boehringer Ingelheim, and Sanofi. TH reports personal fees from GSK, Mundipharma, and Orion Pharma. J‐CI received personal fees from Eurofarma Argentina, Faes Farma, and nonfinancial support from Laboratorio Casasco Argentina and Sanofi. PK has received personal fees from Adamed, Berlin Chemie Menarini, AstraZeneca, Boehringer Ingelheim, Chiesi, Lekam, Novartis, Orion, Polpharma, and Teva. DL‐L reports personal fees and/or grants from Allakos, Amstrong, AstraZeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grünenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Gossamer, TEVA, Boehringer Ingelheim, and the Purina institute. JM declares fees and/or grants from Sanofi‐Genzyme, Regeneron, Novartis, Allakos grants, Mylan Pharma, Uriach Group, Mitsubishi‐Tanabe, Menarini, UCB, AstraZeneca, GSK, and MSD. RN serves in the speaker's bureau for Optinose and as consultant/advisory board for Sanofi, Regeneron, GSK, and AstraZeneca. YO reports personal fees and/or grants from Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, EizaiCo.,Ltd., Kyorin Co., Ltd., Tiho Co., Ltd., Yakuruto Co., Ltd., and Yamada Bee Farm. NP has received personal fees and/or grants from Novartis, Nutricia, HAL Allergy, Menarini/Faes Farma, Sanofi, Mylan/MEDA, Biomay, AstraZeneca, GSK, MSD, ASIT biotech, Boehringer Ingelheim, Gerolymatos International SA, and Capricare. OP reports grants and/or personal fees from ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, Anergis SA, ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, BencardAllergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, MEDA Pharma/Mylan, Mobile Chamber Experts (a GALEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL, Novartis, and Sanofi Aventis. JS reports personal fees from Mylan. MHS has received grants and/or personal fees from ALK, Allergopharma, ASIT Biotech, Regeneron, Merck, Immune Tolerance Network. TZ serves as a member of the WHO‐Initiative "Allergic Rhinitis and Its Impact on Asthma" (ARIA), the German Society for Allergy and Clinical Immunology (DGAKI), head of the European Centre for Allergy Research Foundation (ECARF), president of the Global Allergy and Asthma European Network (GALEN), and serves in the committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). All other authors have no conflict of interest within the scope of the submitted work. 2 2
(Peer reviewed)